What Makes Vaxcyte (PCVX) An Investment Bet?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2024 investor letter.
Vaxcyte Inc. (PCVX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 8,689,190 | $992,913,741 | +6% | 11.44% |
| 2. | Darwin Global Management Abhishek Trehan | 2,198,187 | $251,186,828 | +6% | 20.42% |
| 3. | Perceptive Advisors Joseph Edelman | 2,027,608 | $231,694,766 | +9% | 4.9% |
| 4. | Driehaus Capital Richard Driehaus | 1,721,296 | $196,692,494 | -12% | 1.68% |
| 5. | VenBio Select Advisor Kurt Von Emster | 1,175,000 | $134,267,250 | +105% | 1.95% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 937,500 | Large Shareholder | 5,156,553 | 2020-06-16 | Filing | |
| $16.00 | 12,500 | Director | 4,168,718 | 2020-06-16 | Filing | |
| $16.00 | 93,000 | Director | 2,222,967 | 2020-06-16 | Filing | |
| $16.00 | 250,000 | Director | 2,309,554 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.24 | 280 | Officer | 109,491 | 2024-12-18 | Filing | |
| $89.31 | 3,157 | Officer | 109,771 | 2024-12-18 | Filing | |
| $88.70 | 3,373 | Officer | 112,928 | 2024-12-18 | Filing | |
| $87.26 | 1,190 | Officer | 116,301 | 2024-12-18 | Filing | |
| $93.60 | 154 | Officer, Director | 136,215 | 2024-12-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,213,365 | $892,599,345 | 0.06% | |
| 2. | 8,575,847 | $538,563,192 | 0.01% | |
| 3. | 8,452,371 | $530,808,899 | 0.01% | |
| 4. | 6,981,376 | $438,407,264 | 0.26% | |
| 5. | 4,431,920 | $278,324,577 | 0.05% |
News See All
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Should You Consider Investing in Vaxcyte (PCVX)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, everyone. My name is Bo and I will be your conference operator today.
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, everyone. My name is Bo and I will be your conference operator today.
5 Best Russell 2000 Stocks To Buy According To Hedge Funds
In this article, we discuss 5 best Russell 2000 stocks to buy.
5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
Below we present the list of 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. My name is Lisa, and I will be your conference operator today.
Billionaire Hedge Funds
